Need To Redefine Recipe For Success In Korean Biotech?
Executive Summary
In South Korea, success and failure in the bioventure sector seems to be measured differently to elsewhere, while other legal and investment hurdles remain, and some experts are now pointing to the need for change if the industry is to move on to the next phase.
You may also be interested in...
SillaJen IPO Priced Low But Hopes High As Pexa-Vec Progresses
SillaJen, a South Korean venture that has been under investors' radars, is set to float at the lower end of its range as investors focus on the potential of its lead asset Pexa-Vec for liver cancer.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.